home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Meetings and Conferences  
 

Intelligent Drug Development: A New Service Paradigm for Small Pharma

 
  June 21, 2023  
     
 
Xtalks, online
2023 -7-27


Small pharma, including emerging, virtual and small biotechnology companies, navigate a fragmented vendor network on the journey to Phase II trials, often relying on specialty consultants to assist. But managing multiple contract development and manufacturing organizations (CDMO) and independent consultants across disciplines still doesn’t provide a small pharma sponsor with the breadth of expertise and strategic planning needed to address the complexity of early clinical development.
 
A new paradigm, intelligent drug development, focuses on Phases I and II to achieve proof-of-concept (POC) as efficiently as possible, completing all learning required to plan an effective and complete Phase III program. In this model, small pharma has on-demand access to an aligned and integrated multi-disciplinary team that builds and drives a strategic plan. This strategic team enhances scientific knowledge by maximizing cross-disciplinary interaction, efficiently deploying expert resources and ensuring maximum flexibility, coordination and speed to help small pharma efficiently and effectively execute Phase I and II studies.
 
This webinar will use case studies and hypothetical scenarios to illustrate how the strategic team works with small pharma sponsors to build the strategic plan, select and coordinate partners from the fragmented vendor space to meet key milestones and help interpret the emerging clinical data to lay the foundations for the next stages of clinical and drug product development.
 
Join this webinar to discover a new paradigm, intelligent drug development, designed to support small pharma in efficiently navigating early clinical development.
 
 
Organized by: Xtalks
Invited Speakers: Gary M. Klaich, PhD, Senior Nonclinical Strategy Director, Strategic Development Consulting, PPD, part of Thermo Fisher Scientific Kevin M. Kane, PhD, CMC Strategy Director, Strategic Development Consulting, PPD, part of Thermo Fisher Scientific
 
Deadline for Abstracts: 2023 -7-27
 
Registration: Free registration
E-mail: ajuurinen@xtalks.com
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.